English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

lzheimer’s disease (AD) treatment and prevention research has reached a tipping point. Federal funding in the US for AD study has increased exponentially over the past several years. Public and private institutions, including the Alzheimer’s Association, are advocating for diversifying discovery work on novel biomarkers and treatment targets. Early career and established researchers have joined force in the quest for an effective early therapy for AD. What the field critically needs is a platform to recruit a large number of study participants to accelerate this research effort. The ideal platform should be scalable and cost-effective, allowing efficient testing of multiple new treatments simultaneously. The Trial-Ready Cohort for Preclinical/prodromal Alzheimer’s Disease (TRC-PAD) project may help address this critical need.

ACCELERATING PRECLINICAL ALZHEIMER’S CLINICAL TRIALS THROUGH A TRIAL-READY COHORT WITH DIVERSE REPRESENTATION